Rheumatoid Arthritis Pharmacological Management

Core Treatment Principles

The American College of Rheumatology recommends starting therapy with DMARDs immediately upon diagnosis of rheumatoid arthritis, with methotrexate as the anchor drug in most patients, aiming for sustained remission or low disease activity within 6 months 1, 2

The European League Against Rheumatism (EULAR) recommends targeting remission or low disease activity as the primary therapeutic endpoint, assessed using validated composite measures (DAS28, CDAI, or SDAI) 1, 3
The EULAR guidelines suggest monitoring disease activity every 1-3 months during active disease; if no improvement occurs by 3 months or target is not reached by 6 months, therapy must be adjusted 1, 3

The American College of Rheumatology recommends methotrexate as the first DMARD initiated in patients with moderate-to-high disease activity, unless contraindicated 1, 2, 4
The EULAR guidelines recommend starting with oral methotrexate at an initial dose, then titrating to at least 15 mg weekly within 4-6 weeks for optimal efficacy 2, 5

The EULAR guidelines state that hydroxychloroquine has a limited role in rheumatoid arthritis management, primarily reserved for patients with low disease activity 1, 2
For DMARD-naive patients with low disease activity, hydroxychloroquine is conditionally recommended over other csDMARDs due to better tolerability and more favorable risk profile 2, 5

The EULAR guidelines recommend short-term glucocorticoids (<3 months) may be used when initiating or changing csDMARDs, but should be tapered as rapidly as clinically feasible and are not recommended for systematic use 1, 2
The American College of Rheumatology conditionally recommends initiation of csDMARD without short-term glucocorticoids over routine addition of glucocorticoids for DMARD-naive patients with moderate-to-high disease activity 2, 5

The EULAR guidelines recommend initiating methotrexate monotherapy (oral, titrate to ≥15 mg weekly within 4-6 weeks) with folic acid for DMARD-naive patients with moderate-to-high disease activity 1, 2
For patients with inadequate response to methotrexate, the EULAR guidelines recommend adding a biologic DMARD (TNF inhibitor, abatacept, or tocilizumab) to methotrexate 1, 6, 7

The EULAR guidelines state that the treatment strategy (tight control with frequent monitoring and rapid escalation) appears more important than the specific drug chosen in achieving optimal outcomes 1
The American College of Rheumatology recommends a step-up approach rather than routine upfront combination with biologics in most patients 1, 2